Table 3:

List of trials conducted with anti PD-1 (in combination or in monotherapy in STS). Data of sunitinib in monotherapy in STS is also included for comparative purpose.

Study	Regimen	N	mPFS (m)	3-m PFS rate	6-m PFS rate	ORR (RECIST)	Included Subtypes	Responding Subtypes
Tawbi(37) (SARC028)	pembro	42	4.2	55%	32%	18% 7/40	UPS, LMS, LPS, SS	UPS, LPS, SS
D’Angelo(38) (A091401)	nivolumab	43	1.7	~ 35%	15%	5% 2/38	>10 (UPS, LMS, SS, LPS, ES…)	ASPS, LMS
Ben-Ami(75)	nivolumab	12	1.8	0%	0%	0%	uLMS	NA
George(45)	sunitinib	50	1.8	39%	22%	2% 1/48	Several: 23% LMS; 8% SS	DSRCT
Merchant(76)	ipilimumab	17	UNK	UNK	UNK	0% 0/17	Pediatric several SS, CCS, …	NA
D’Angelo(38) (A091401)	nivolumab- ipilimumab	42	4.1	~ 60%	28%	16% 6/38	>10 (UPS, LMS, SS, LPS, ES…)	LMS, UPS, Myxo, Angio
Wilky(40)	axitinib- pembro	33	4.7	65.6%	50%	25% 8/32	Several: 36% ASPS	ASPS, LMS, ES
Martin-Broto(43) (IMMUNOSARC)	nivolumab- sunitinib	50	5.9	69%	50%	11% 5/46	Several: 18% SS, 6% ASPS, UPS, ES…	ASPS, Angio, ECM, SS
Toulmonde(77)	metronomic cyclo-pembro	57	1.4	UNK	0% (LMS; UPS), 14.3%(Other STS)	2% 1/48	LMS, UPS, other STS, GIST	SFT
Pollack(44)	doxorubicin- pembro	37	8.1	UNK	UNK	22% 8/37	Several STS	UNK

UNK (unknown); NA (not applicable); Pembro (pembrolizumab); Cyclo (cyclophosphamide); ASPS (alveolar soft-part sarcoma); UPS (undifferentiated pleomorphic sarcoma); uLMS (uterine leiomyosarcoma); LMS (leiomyosarcoma); Angio (angiosarcoma); Myxo (myxofibrosarcoma); SS (synovial sarcoma); ECM (extraskeletal myxoid chondrosarcoma); LPS (liposarcoma); ES (epithelioid sarcoma).